- The disease
- NEURACTHEL is being developed for neurological and endocrinological disorders, which are broad categories covering conditions involving the brain and nervous system or hormone-producing glands and their target organs. The specific disease or diseases within these categories that Clinuvel intends to address with NEURACTHEL have not been publicly disclosed in the input data available. No clinical trial has been registered for NEURACTHEL in this indication to date.
- What the asset is trying to do
- NEURACTHEL is described as an analog of adrenocorticotropic hormone (ACTH), a naturally occurring peptide produced by the pituitary gland that regulates cortisol release and has receptors distributed across the nervous system and other tissues (per Clinuvel public disclosures). As a synthetic analog, it is designed to mimic or modulate ACTH activity, though the precise receptor targets and intended pharmacological action for this specific asset have not been publicly detailed in the input data. Clinuvel's existing approved drug, SCENESSE (afamelanotide), is a melanocortin receptor agonist peptide, placing NEURACTHEL within a related but distinct peptide therapeutic class.
- What the trial is measuring, and why it matters
- No clinical trial has been registered or initiated for NEURACTHEL; the asset is described as preclinical. As a result, no trial endpoints, outcome measures, or study design details are currently available from public sources.
- Efficacy benchmarks in this setting
- Because NEURACTHEL targets neurological and endocrinological disorders as a broad category, and no specific indication has been disclosed, no single approved-therapy benchmark applies at this stage. For context, approved ACTH-based therapies in neurology include Acthar Gel (repository corticotropin injection), which is approved in the United States for conditions including infantile spasms and multiple sclerosis relapse (per US FDA prescribing information for Acthar Gel). Efficacy figures for approved therapies in any specific neurological or endocrinological condition that NEURACTHEL may eventually target are not available from the input data. Early-stage preclinical data, when available, are not statistically comparable to figures from approved or late-stage therapies.